Rare disease biotech Aldeyra Therapeutics sets terms for $22 million IPO

By
A A A

Aldeyra Therapeutics, a clinical-stage biotech developing treatments for rare skin and eye diseases, announced terms for its IPO on Monday. The Burlington, MA-based company plans to raise $22 million by offering 2 million shares at a price range of $10 to $12. At the midpoint of the proposed range, it would command a fully diluted market value of $71 million. Aldeyra Therapeutics, which was founded in 2004, plans to list on the NASDAQ under the symbol ALDX. Aldeyra Therapeutics initially filed confidentially on December 4, 2013 and changed its name from Aldexa Therapeutics on March 4, 2014. Aegis Capital is the sole bookrunner on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks: ALDX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Vox Media Acquires Re/Code
Vox Media Acquires Re/Code          

Stocks

Referenced

100%

Most Active by Volume

68,295,916
  • $16.74 ▲ 1.45%
62,491,455
  • $45.93 ▼ 24.20%
60,733,203
  • $57.155 ▲ 21.81%
44,713,400
  • $132.045 ▲ 1.87%
38,827,100
  • $5.28 ▲ 7.32%
33,433,686
  • $67.38 ▲ 1.94%
31,309,870
  • $34.95 ▲ 0.81%
28,346,742
  • $8.60 ▲ 1.06%
As of 5/27/2015, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com